143 related articles for article (PubMed ID: 33436659)
1. Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy.
Yoo SH; Kang SY; Yoon J; Kim TY; Cheon GJ; Oh DY
Sci Rep; 2021 Jan; 11(1):296. PubMed ID: 33436659
[TBL] [Abstract][Full Text] [Related]
2. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study.
Yoo SH; Kang SY; Cheon GJ; Oh DY; Bang YJ
J Nucl Med; 2020 Jan; 61(1):33-39. PubMed ID: 31201247
[TBL] [Abstract][Full Text] [Related]
3. Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication.
Park S; Ha S; Kwon HW; Kim WH; Kim TY; Oh DY; Cheon GJ; Bang YJ
J Nucl Med; 2017 Jun; 58(6):899-904. PubMed ID: 28572288
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of interim
Lee SY; Seo HJ; Kim S; Eo JS; Oh SC
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e302-e309. PubMed ID: 29226597
[TBL] [Abstract][Full Text] [Related]
6. Metabolic tumor burden on postsurgical PET/CT predicts survival of patients with gastric cancer.
Sun G; Cheng C; Li X; Wang T; Yang J; Li D
Cancer Imaging; 2019 Mar; 19(1):18. PubMed ID: 30902116
[TBL] [Abstract][Full Text] [Related]
7. Value of Intratumoral Metabolic Heterogeneity and Quantitative
Pinho DF; King B; Xi Y; Albuquerque K; Lea J; Subramaniam RM
AJR Am J Roentgenol; 2020 Apr; 214(4):908-916. PubMed ID: 32069078
[No Abstract] [Full Text] [Related]
8. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
9. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
10. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study.
Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R
Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262
[No Abstract] [Full Text] [Related]
11. Texture analysis of
Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
[TBL] [Abstract][Full Text] [Related]
12. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
13. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
[TBL] [Abstract][Full Text] [Related]
14. Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.
Manoharan V; Lee S; Chong S; Yap J; Coupe N; Wilson R; Merrett N; Ng W; Lin M
Ann Nucl Med; 2017 May; 31(4):315-323. PubMed ID: 28299585
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral heterogeneity in
Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
[TBL] [Abstract][Full Text] [Related]
16. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
17. Volumetric parameters on
Liu G; Hu Y; Cheng X; Wang Y; Gu Y; Liu T; Shi H
BMC Cancer; 2019 Aug; 19(1):790. PubMed ID: 31395059
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline
Garcia-Vicente AM; Pérez-Beteta J; Amo-Salas M; Molina D; Jimenez-Londoño GA; Soriano-Castrejón AM; Pena Pardo FJ; Martínez-González A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):73-79. PubMed ID: 29102649
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer.
Moon SY; Joo KR; So YR; Lim JU; Cha JM; Shin HP; Yang YJ
Clin Nucl Med; 2013 Oct; 38(10):778-83. PubMed ID: 24107806
[TBL] [Abstract][Full Text] [Related]
20. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study.
Ott K; Herrmann K; Lordick F; Wieder H; Weber WA; Becker K; Buck AK; Dobritz M; Fink U; Ulm K; Schuster T; Schwaiger M; Siewert JR; Krause BJ
Clin Cancer Res; 2008 Apr; 14(7):2012-8. PubMed ID: 18381939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]